m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway.

MLA

Huang, Tinghui, et al. “M6A Methyltransferase METTL3 Promotes Non-Small-Cell Lung Carcinoma Progression by Inhibiting the RIG-I-MAVS Innate Immune Pathway.” Translational Oncology, vol. 51, Jan. 2025, p. 102230. EBSCOhost, https://doi.org/10.1016/j.tranon.2024.102230.

APA

Huang, T., Ao, X., Liu, J., Sun, C., Dong, Y., Yin, X., Zhang, Y., Wang, X., Li, W., Cao, J., Pan, F., Hu, Z., Guo, Z., & He, L. (2025). m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway. Translational Oncology, 51, 102230. https://doi.org/10.1016/j.tranon.2024.102230

Chicago

Huang, Tinghui, Xudong Ao, Jie Liu, Chuancheng Sun, Yunfei Dong, Xuechen Yin, Yan Zhang, et al. 2025. “M6A Methyltransferase METTL3 Promotes Non-Small-Cell Lung Carcinoma Progression by Inhibiting the RIG-I-MAVS Innate Immune Pathway.” Translational Oncology 51 (January): 102230. doi:10.1016/j.tranon.2024.102230.